Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II Trial

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

23 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-05-31

Study Completion Date

2016-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the efficacy and safety of temozolomide in patient with relapsed or advanced anaplastic oligodendroglioma and anaplastic oligoastrocytoma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Temozolomide in Treating Patients With Anaplastic Oligodendroglioma

NCT00003465

Brain and Central Nervous System Tumors

COMPLETED PHASE2

Efficacy Study of Radiotherapy Alone Versus CCRT With Temozolomide in Grade III Gliomas Without 1p/19q Codeletion

NCT01534845

Anaplastic Glioma of Brain Loss of Chromosomes 1p/19q

UNKNOWN PHASE2

Temozolomide in Treating Patients With Newly Diagnosed Anaplastic Oligodendroglioma or Mixed Oligoastrocytoma

NCT00400816

Central Nervous System Tumors Brain Tumor

COMPLETED PHASE2

Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma

NCT04388475

Recurrent Malignant Glioma Brain Glioblastoma

COMPLETED PHASE2

Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors

NCT00003731

Brain and Central Nervous System Tumors

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patient with relapsed or advanced anaplastic oligodendroglioma and anaplastic oligoastrocytoma will be enrolled. Enrolled patients will begin on temozolomide 200 mg/m2/d in a fasting state for 5 consecutive days (1,000 mg/m2 per 28-day cycle). Patients who were previously treated with any chemotherapy initially received temozolomide 150 mg/m2/d for 5 days (750 mg/m2 per cycle).Patients will be receving a total 6 cycles of chemotheray (4weeks/cycle \* 6cycles = 24weeks). If the patients shows responses to Temozolomide, treatment can be continued by the investigator's discretion.

During the administration of Temozolomide, vital signs, physical examination, ECOG performance status, height, weight, hematology and chemistry test, adverse events and concomitant drugs will be evaluated every four weeks. Brain MRI for tumor assessment will be performed once every 12 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anaplastic Oligodendroglioma Anaplastic Oligoastrocytoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Temozolomide

Temozolomide 200 mg/m2/d in a fasting state for 5 consecutive days

Group Type EXPERIMENTAL

Temozolomide

Intervention Type DRUG

Temozolomide 200 mg/m2/d in a fasting state for 5 consecutive days (1,000 mg/m2 per 28-day cycle).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Temozolomide

Temozolomide 200 mg/m2/d in a fasting state for 5 consecutive days (1,000 mg/m2 per 28-day cycle).

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Temodal

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically proven anaplastic oligodendroglioma or oligoastrocytoma
* Progressed or relapsed after surgery or radiation therapy
* Female or male aged 20 years or over
* At least 1 measurable mass lesion
* ECOG performance status 0-3
* Adequate organ function
* absolute neutrophil count \> 1,500/μL
* platelet count \> 75,000/μL
* hemoglobin greater than 9 g/dL or 900g/L
* serum creatinine less than 1.5 times the upper limit of laboratory normal
* total serum bilirubin less than 1.5 times the upper limit of laboratory normal
* AST or ALT less than three times the upper limit of laboratory normal